Inhibikase Therapeutics, Inc.
IKT- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001750149
No open-market purchases or sales by Inhibikase Therapeutics, Inc. insiders were filed in the last 90 days; 105 institutions reported holding it in 13F filings for Q2 2026, worth $239.2M in total; no superinvestor holds it.
Holders of 5% or more of IKT
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Inhibikase Therapeutics, Inc., largest stake first. The change is against the holder's previous filing.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Ra Capital Management, L.P. | 13G/A | 9.90%14.7M shares | −6.00 ppfrom 15.90% | Jul 17, 20262 filings | Jul 31, 2026 | SEC |
| Commodore Capital LP | 13G/A | 9.90%14.1M shares | – | May 15, 20261 filing | May 15, 2026 | SEC |
| ADAR1 Capital Management, LLC | 13G/A | 9.90%13.9M shares | 0.00 ppfrom 9.90% | Feb 14, 20254 filings | May 15, 2026 | SEC |
| Fairmount Funds Management LLC | 13G/A | 9.90%12.5M shares | 0.00 ppfrom 9.90% | Feb 14, 20252 filings | Feb 17, 2026 | SEC |
| Sands Capital Life Sciences Pulse Fund II, L.P. | 13G/A | 9.30%13.0M shares | −1.50 ppfrom 10.80% | Aug 13, 20253 filings | Aug 13, 2026 | SEC |
| Perceptive Advisors LLC | 13G/A | 6.90%10.3M shares | −2.00 ppfrom 8.90% | Feb 17, 20263 filings | Aug 14, 2026 | SEC |
| Trails Edge Capital Partners, LP | 13G/A | 6.10%8.06M shares | +1.00 ppfrom 5.10% | Dec 31, 20252 filings | May 15, 2026 | SEC |
| BlackRock, Inc. | 13G | 5.90%7.77M shares | New | Jul 28, 20261 filing | Jul 28, 2026 | SEC |
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
23 Schedule 13D and 13G filings on Inhibikase Therapeutics, Inc., newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| Aug 14, 20265:19 PM ET | Perceptive Advisors LLCand 2 others | 13G/A | 6.90%10.3M shares | −2.00 ppfrom 8.90% | Jun 30, 2026 | SEC |
| Aug 14, 20264:40 PM ET | Nantahala Capital Management, LLCand 2 others | 13G/A | 4.30%5.81M shares | −1.38 ppfrom 5.68%Below 5% | Jun 30, 2026 | SEC |
| Aug 13, 202611:49 AM ET | Sands Capital Life Sciences Pulse Fund II, L.P.and 2 others | 13G/A | 9.30%13.0M shares | −1.50 ppfrom 10.80% | Jun 30, 2026 | SEC |
| Jul 31, 20264:33 PM ET | Ra Capital Management, L.P.and 3 others | 13G/A | 9.90%14.7M shares | −6.00 ppfrom 15.90% | Jul 29, 2026 | SEC |
| Jul 28, 20264:44 PM ET | BlackRock, Inc. | 13G | 5.90%7.77M shares | New | Jun 30, 2026 | SEC |
| Jul 17, 20265:52 PM ET | Ra Capital Management, L.P.and 3 others | 13G | 15.90%25.0M shares | New | Jul 10, 2026 | SEC |
| May 15, 20268:13 PM ET | ADAR1 Capital Management, LLCand 2 others | 13G/A | 9.90%13.9M shares | 0.00 ppfrom 9.90% | Mar 31, 2026 | SEC |
| May 15, 20264:15 PM ET | Trails Edge Capital Partners, LPand 2 others | 13G/A | 6.10%8.06M shares | +1.00 ppfrom 5.10% | Mar 31, 2026 | SEC |
| May 15, 20264:11 PM ET | Commodore Capital LPand 3 others | 13G/A | 9.90%14.1M shares | – | Mar 31, 2026 | SEC |
| May 15, 20264:00 PM ET | Perceptive Advisors LLCand 2 others | 13G/A | 8.90%12.6M shares | −1.09 ppfrom 9.99% | Mar 31, 2026 | SEC |
| Feb 17, 20266:22 PM ET | ADAR1 Capital Management, LLCand 2 others | 13G/A | 9.90%12.7M shares | 0.00 ppfrom 9.90% | Dec 31, 2025 | SEC |
| Feb 17, 20264:30 PM ET | Fairmount Funds Management LLCand 3 others | 13G/A | 9.90%12.5M shares | 0.00 ppfrom 9.90% | Dec 31, 2025 | SEC |
| Feb 17, 20264:00 PM ET | Perceptive Advisors LLCand 2 others | 13G/A | 9.99%12.8M shares | – | Dec 31, 2025 | SEC |
| Feb 13, 20265:04 PM ET | Nantahala Capital Management, LLCand 2 others | 13G/A | 5.68%7.04M shares | −1.86 ppfrom 7.54% | Dec 31, 2025 | SEC |
| Feb 13, 202611:30 AM ET | Sands Capital Life Sciences Pulse Fund II, L.P.and 2 others | 13G/A | 10.80%13.0M shares | −3.90 ppfrom 14.70% | Dec 31, 2025 | SEC |
| Dec 31, 20255:00 PM ET | Trails Edge Capital Partners, LPand 2 others | 13G | 5.10%6.15M shares | New | Dec 23, 2025 | SEC |
| Aug 14, 20258:27 PM ET | ADAR1 Capital Management, LLCand 2 others | 13G/A | 9.90%7.74M shares | −0.09 ppfrom 9.99% | Jun 30, 2025 | SEC |
| Aug 13, 202511:17 AM ET | Sands Capital Life Sciences Pulse Fund II, L.P.and 2 others | 13G/A | 14.70%10.9M shares | – | Jun 30, 2025 | SEC |
| Feb 14, 20259:04 PM ET | ADAR1 Capital Management, LLCand 2 others | 13G | 9.99%6.99M shares | New | Dec 31, 2024 | SEC |
| Feb 14, 20255:35 PM ET | Armistice Capital, LLCand 1 other | 13G/A | 4.99%3.53M shares | –Below 5% | Dec 31, 2024 | SEC |
| Feb 14, 20254:32 PM ET | Nantahala Capital Management, LLCand 2 others | 13G | 7.54%5.30M shares | New | Dec 31, 2024 | SEC |
| Feb 14, 20254:08 PM ET | Point72 Asset Management, L.P.and 2 others | 13G/A | 0.00%0 shares | –Below 5% | Dec 31, 2024 | SEC |
| Feb 14, 20253:45 PM ET | Fairmount Funds Management LLCand 3 others | 13G/A | 9.90%7.02M shares | – | Dec 31, 2024 | SEC |
Form 144: proposed insider sales
Notices from officers, directors and other affiliates planning to sell Inhibikase Therapeutics, Inc. shares.
No Form 144 notices for Inhibikase Therapeutics, Inc. are on file.